scholarly journals Plasma Amiloid β42 in Patients with Obstructive Sleep Apnea before and after CPAP-Therapy: Pilot Study

2019 ◽  
Vol 9 (3) ◽  
pp. 205-209 ◽  
Author(s):  
Irina Madaeva ◽  
Natalya Semenova ◽  
Erdem Ukhinov ◽  
Nadezhda Kurashova ◽  
Leonid Sholohov ◽  
...  
Keyword(s):  
Obstructive Sleep Apnea ◽  
Sleep Apnea ◽  
Pilot Study ◽  
Cpap Therapy ◽  
Obstructive Sleep ◽  
Before And After

430 Outcome of Sleep-Wake Pattern in Obstructive Sleep Apnea Patients after Positive Airway Pressure Therapy using Actigraphy

SLEEP ◽  
2021 ◽  
Vol 44 (Supplement_2) ◽  
pp. A170-A170
Author(s):  
Narumol Luekitinun ◽  
Kanlaya Panjapornpon ◽  
Pattharaphong Plurksathaporn ◽  
Rungaroon Tangsrikertikul ◽  
Wanlana Tongkien ◽  
...  
Keyword(s):  
Obstructive Sleep Apnea ◽  
Sleep Apnea ◽  
Sleep Quality ◽  
Airway Pressure ◽  
Positive Airway Pressure ◽  
Matched Pair ◽  
Cpap Therapy ◽  
Obstructive Sleep ◽  
Before And After ◽  
Sleep Parameters

Abstract Introduction The initial phase of continuous positive airway pressure (CPAP) therapy in patients with obstructive sleep apnea (OSA) may affect sleep parameters and PAP compliance. Actigraphy is a validated method using accelerometer to objectively measure sleep parameters in patients with a range of sleep disorders, including OSA, particularly to follow-up after treatment. We compare sleep parameters from actigraphy, sleep log, sleep diary, Epworth Sleepiness Scale (ESS), Pittsburgh Sleep Quality Index (PSQI), heart rate and blood pressure in OSA patients before and after CPAP therapy for 1 week. Methods This pilot study have been prospectively performed at Central Chest Institute of Thailand (CCIT) since June to November 2020. Adult OSA patients, diagnosed by ICSD-3 criteria and achieved optimal or good CPAP pressure titration from split-night polysomnography (PSG), were informed and consent to wear actigraphy before and after CPAP therapy each for 1 week. Clinical and sleep parameters were recorded and analyzed using Wilcoxon matched-pair signed-rank and Mann Whitney U test. P-value < 0.05 was considered to have statistical significance. Results All 11 OSA patients participated in this study. Most patients were male (63.6%), hypertension (54.5%) and dyslipidemia (45.4%). Means of age, body mass index (BMI), ESS, PSQI, apnea hypopnea index (AHI), nadir SpO2, and CPAP usage were 45.5 ± 15.9 years, 29.1 ± 5.2 kg/m2, 10.8 ± 3.9, 7.7 ± 2.9, 65.2 ± 37.7 events/h, 82.3 ± 10.8 % and 9.5 ± 3.1 cmH2O, respectively. Comparing before and after 1-week CPAP therapy, an average number of wake bouts ((NWB), 48.4 vs 38 events, p=0.010), ESS (11 vs 9, p=0.035) and PSQI (8 vs 4, p=0.005) were significantly decrease. Additionally, when comparing between poor and good CPAP compliance group, NWB (55.1 vs 36.3 events, p=0.036) and the difference of wake after sleep onset (WASO, 10.5 vs -0.11 min, p=0.035) were significantly decrease. Conclusion OSA patients treated with CPAP for 1-week experienced marked improvement in sleepiness, sleep quality and nighttime awakening. Support (if any):

scholarly journals Morning pentraxin3 levels reflect obstructive sleep apnea–related acute inflammation

2014 ◽  
Vol 117 (10) ◽  
pp. 1141-1148 ◽  
Author(s):  
Yusuke Kobukai ◽  
Takashi Koyama ◽  
Hiroyuki Watanabe ◽  
Hiroshi Ito
Keyword(s):  
Obstructive Sleep Apnea ◽  
Sleep Apnea ◽  
Acute Inflammation ◽  
High Sensitivity ◽  
Apnea Hypopnea Index ◽  
Cpap Therapy ◽  
Reactive Protein ◽  
Obstructive Sleep ◽  
Before And After ◽  
Hs Crp

This study investigated morning levels of pentraxin3 (PTX3) as a sensitive biomarker for acute inflammation in patients with obstructive sleep apnea (OSA). A total of 61 consecutive patients with OSA were divided into two groups: non-to-mild ( n = 20) and moderate-to-severe ( n = 41) OSA based on their apnea-hypopnea index (AHI) score. Those patients with moderate-to-severe OSA were further divided into continuous positive airway pressure (CPAP) treated ( n = 21) and non-CPAP-treated ( n = 20) groups. Morning and evening serum PTX3 and high-sensitivity (hs) C-reactive protein (CRP) levels were measured before and after 3 mo of CPAP therapy. The baseline hs-CRP and PTX3 levels were higher in patients with moderate-to-severe OSA than in those with non-to-mild OSA. Moreover, the serum PTX3 levels, but not the hs-CRP levels, were significantly higher after than before sleep in the moderate-to-severe OSA group (morning PTX3, 1.96 ± 0.52; evening PTX3, 1.71 ± 0.44 ng/ml). OSA severity as judged using the AHI was significantly correlated with serum PTX3 levels but not hs-CRP levels. The highest level of correlation was found between the AHI and morning PTX3 levels ( r = 0.563, P < 0.001). CPAP therapy reduced evening and morning serum hs-CRP and PTX3 levels in patients with moderate-to-severe OSA; however, the reduction in PTX3 levels in the morning was greater than that in the evening (morning −29.8 ± 16.7% vs. evening −12.6 ± 26.8%, P = 0.029). Improvement in the AHI score following CPAP therapy was strongly correlated with reduced morning PTX3 levels( r = 0.727, P < 0.001). Based on these results, morning PTX3 levels reflect OSA-related acute inflammation and are a useful marker for improvement in OSA following CPAP therapy.

scholarly journals Psychometric properties of the Lithuanian version of Sleep Apnea Quality of Life Index (a pilot study)

Medicina ◽  
2008 ◽  
Vol 44 (4) ◽  
pp. 296 ◽  
Author(s):  
Tomas Balsevičius ◽  
Virgilijus Uloza ◽  
Raimundas Sakalauskas ◽  
Skaidrius Miliauskas ◽  
Regina Rėklaitienė ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Obstructive Sleep Apnea ◽  
Sleep Apnea ◽  
Pilot Study ◽  
Tissue Ablation ◽  
Life Index ◽  
Obstructive Sleep ◽  
Before And After ◽  
Quality Of Life Index

Objective. To arrange and test for its psychometric properties Lithuanian version of Sleep Apnea Quality of Life Index and assess quality of life among snoring and obstructive sleep apnea patients before and after the treatment. Material and methods. Cross-cultural adaptation of Lithuanian version of Calgary Sleep Apnea Quality of Life Index was accomplished according to generally accepted methodology. In total, 36 (29 males and 7 females) patients (mean age, 41.1±9.7 years) suffering from socially disturbing snoring and obstructive sleep apnea were included into the study. All patients underwent complete full-night polysomnography (mean apnea/hypopnea index, 12.7±11.2) and were treated with two sessions of radiofrequency tissue ablation at the palatal and tong base (if it was necessary) levels. Lithuanian version of the Calgary Sleep Apnea Quality of Life Index was presented before the treatment with radiofrequency tissue ablation and in the period of 2 to 3 months after the treatment. Thirty-five patients repeated the same questionnaire after three weeks to assess the reliability of scores. Results. The Cronbach’s α coefficients of internal reliability were above the standard (0.7 for groups) in all subdomains and domains. Test-retest correlation coefficients for each domain (ranged from 0.92 to 0.94) were statistically significant (P<0.0001). Lithuanian version of the questionnaire was found to be responsive to clinical change. A statistically significant difference in the mean Sleep Apnea Quality of Life Index scores in the study group patients before and after the surgery was found in all daily functioning subdomains and social interactions domains. Conclusions. Overall, the results of the present pilot study demonstrate that the Lithuanian version of Sleep Apnea Quality of Life Index is applicable for clinical purposes.

Sleep spindle density before and after CPAP titration in severe obstructive sleep apnea: A pilot study

2015 ◽  
Vol 16 ◽  
pp. S355-S356
Author(s):  
S. Chokroverty ◽  
S. Bhat ◽  
D. Donnelly ◽  
D. Gupta ◽  
M. Rubenstein ◽  
...  
Keyword(s):  
Obstructive Sleep Apnea ◽  
Sleep Apnea ◽  
Pilot Study ◽  
Severe Obstructive Sleep Apnea ◽  
Sleep Spindle ◽  
Cpap Titration ◽  
Obstructive Sleep ◽  
Before And After

scholarly journals Interleukin-6 and vitamin D serum levels in patients with obstructive sleep apnea syndrome before and after long-term continuous positive airway pressure treatment

2020 ◽  
Author(s):  
Ourania S Kotsiou ◽  
Dimitra I. Siachpazidou ◽  
Chaido Pastaka ◽  
Eudoxia Gogou ◽  
Maria Kechagia ◽  
...  
Keyword(s):  
Vitamin D ◽  
Obstructive Sleep Apnea ◽  
Sleep Apnea ◽  
Sleep Apnea Syndrome ◽  
Serum Levels ◽  
Cpap Therapy ◽  
Obstructive Sleep ◽  
Before And After ◽  
Apnea Syndrome

Abstract Background: Hypoxia induces the production of adipocyte-derived mediators such as IL-6 in obstructive sleep apnea syndrome (OSAS). Low serum 25-hydroxyvitamin D (25(OH)D) levels have been linked to OSAS susceptibility. No data exist to assess whether there has been a correlation between vitamin D and IL-6 serum levels. The effect of CPAP therapy on IL-6 or 25(OH)D levels has yet to be investigated sufficiently in OSAS. We aimed at determining the serum levels of 25(OH)D and IL-6 in OSAS patients compared to non-apneic controls, investigating a possible correlation between 25(OH)D and IL-6 levels and evaluating the changes in IL-6 and 25(OH)D concentrations after twelve months of CPAP therapy in OSAS patients.Methods: 15 OSAS patients diagnosed by polysomnography and 15 non-apneic controls were included in the study. Serum IL-6 and 25(OH)D levels were measured before and after twelve-month CPAP therapy in the whole population and OSAS group, respectively.Results: IL-6 levels were significantly elevated in the OSAS group than the controls. IL-6 levels were positively correlated with OSAS severity, nocturnal hypoxemia, and body mass index (BMI). No difference was detected in 25(OH)D serum levels between groups. We found no correlation between IL-6 and 25(OH)D serum levels in two groups. No effect on IL-6 or 25(OH)D levels was detect after one year of effective CPAP therapy in OSAS patients.Conclusions: IL-6 levels were correlated with OSAS severity, hypoxemia, and BMI. No correlation between 25(OH)D and IL-6 levels and no effect of long-term CPAP on biomarkers were found in OSAS patients.

Treating Velopharyngeal Inadequacy Using Bilateral Buccal Flap Revision Palatoplasty

2019 ◽  
Vol 4 (5) ◽  
pp. 878-892
Author(s):  
Joseph A. Napoli ◽  
Linda D. Vallino
Keyword(s):  
Systematic Review ◽  
Obstructive Sleep Apnea ◽  
Sleep Apnea ◽  
Cleft Lip ◽  
Cleft Lip And Palate ◽  
A Priori ◽  
Sufficient Evidence ◽  
Obstructive Sleep ◽  
Before And After ◽  
Buccal Flap

Purpose The 2 most commonly used operations to treat velopharyngeal inadequacy (VPI) are superiorly based pharyngeal flap and sphincter pharyngoplasty, both of which may result in hyponasal speech and airway obstruction. The purpose of this article is to (a) describe the bilateral buccal flap revision palatoplasty (BBFRP) as an alternative technique to manage VPI while minimizing these risks and (b) conduct a systematic review of the evidence of BBFRP on speech and other clinical outcomes. A report comparing the speech of a child with hypernasality before and after BBFRP is presented. Method A review of databases was conducted for studies of buccal flaps to treat VPI. Using the principles of a systematic review, the articles were read, and data were abstracted for study characteristics that were developed a priori. With respect to the case report, speech and instrumental data from a child with repaired cleft lip and palate and hypernasal speech were collected and analyzed before and after surgery. Results Eight articles were included in the analysis. The results were positive, and the evidence is in favor of BBFRP in improving velopharyngeal function, while minimizing the risk of hyponasal speech and obstructive sleep apnea. Before surgery, the child's speech was characterized by moderate hypernasality, and after surgery, it was judged to be within normal limits. Conclusion Based on clinical experience and results from the systematic review, there is sufficient evidence that the buccal flap is effective in improving resonance and minimizing obstructive sleep apnea. We recommend BBFRP as another approach in selected patients to manage VPI. Supplemental Material https://doi.org/10.23641/asha.9919352

Sign in / Sign up

Export Citation Format

Share Document